Maxygen's MAXY-G34 for Acute Radiation Syndrome not considered for BARDA award

[News]

Maxygen, Inc. today announced that it has been advised by the Biomedical Advanced Research and Development Authority (BARDA) that Maxygen's proposal for the development of its MAXY-G34 product candidate as a potential medical countermeasure for Acute Radiation Syndrome (ARS) will not be considered for a contract award.

More... (http://www.news-medical.net/news/20111110/Maxygens-MAXY-G34-for-Acute-Radiation-Syndrome-not-considered-for-BARDA-award.aspx)